SAN JOSE, Calif., April 17, 2018 -- According to the latest report published by Credence Research, Inc. “Seborrheic Keratosis Treatment Market - Growth, Future Prospects and Competitive Analysis, 2018-2026,” the global seborrheic keratosis treatment market expected to reach US$ 1,320.8 Mn by 2026.
Market Insights
The global seborrheic keratosis treatment market expected to reach US$ 1,320.8 Mn by 2026. Seborrheic keratosis is one of the most common benign skin growths in adults and its prevalence rises with the increasing age. These growths are normally painless and can be left untreated; however, they could be bothersome depending on size and location, and for aesthetic or cosmetic reasons. The exact cause of seborrheic keratosis is unknown, yet the incidence is directly proportional with advancing age. Seborrheic keratosis also tends to run in heredity. In 2014, seborrheic keratosis was estimated to affect 83 million people and dermatologists reported an average diagnosis of 155 patients per month with the disease in the United States.
Growing preference for cosmetic and aesthetic quotient and high prevalence of seborrheic keratosis are observed to be the key factors driving the seborrheic keratosis treatment market. Although surgical treatments are available in the market to treat seborrheic keratosis, a topical solution (40% hydrogen peroxide – Eskata by Aclaris Therapeutics) is approved by the FDA in 2017, which may augment the market growth due to expected improvement in treatment adherence. Furthermore, Aclaris Therapeutics has also filed an application in the European regulatory agencies for approval. The approval of the topical solution along with the ongoing research for other therapeutics will contribute to the growth of the seborrheic keratosis treatment market during the forecast period.
The global seborrheic keratosis treatment market is segmented into surgical treatments and topical solution treatments. Surgical treatments segment is further categorized into cryosurgery, electrocautery, curettage, and laser ablation. Topical solution treatment segment includes the currently approved 40% hydrogen peroxide solution. While destructive treatments such as cryotherapy and curettage will remain the gold standard for seborrheic keratosis treatment, new therapies such as laser beam treatment and topical applications are anticipated to achieve more efficiency with comfort and convenience for patients.
Based on geographical segmentation, North America dominated the global market with more than 30% market share in 2017, and projected to hold its dominance during the forecast period. High prevalence of seborrheic keratosis and adoption of advanced treatment technologies in the region drives the North America market. Asia Pacific and Latin America markets are anticipated to experience the fastest growth during the forecast period owing to phenomenal growth in demand for skin care and aesthetic products in the regions. The key players in the seborrheic keratosis treatment market include Aclaris Therapeutics, Inc., Cortex Technology ApS, CryoConcepts LP, Cryoswiss GmbH, EpiPharm AG, DRE Medical, Inc., H&O Equipments SA, Orasure Technologies, Inc., Special Medical Technology Co., Ltd., and Wallach Surgical Devices, Inc.
Browse Full Report With TOC, Figures And Tables @ http://www.credenceresearch.com/report/seborrheic-keratosis-treatment-market
Related Reports:
Ultrafast CT Scan Devices Market
Direct-To-Consumer (DTC) Genetic Testing Market
Orthopedic Prosthetic Devices Market
About Us:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.
Contact:
Name: Chris Smith
Designation: Global Sales Manager
E-mail: [email protected]
Ph: +1-800-361-8290
Connect With US:
Web: Credence Research
Facebook @ https://www.facebook.com/CredenceResearch
Twitter @ https://twitter.com/CredenceResearc
LinkedIn @ https://us.linkedin.com/company/credenceresearch
G+ @ https://plus.google.com/+Credenceresearch


How Marco Pharma International Preserves German Homeopathic Traditions in America
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains
Bank of America CEO Brian Moynihan’s 2025 Compensation Rises 17% to $41 Million Amid Strong Profit Growth
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act
Senators Urge CFIUS Review of UAE Investment in Trump-Linked Crypto Firm World Liberty Financial
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle 



